scholarly journals Erratum: Expression of thyrotropin and thyroid hormone receptors in the adipose tissue of patients with morbid obesity and/or type 2 diabetes: effects of weight loss

2010 ◽  
Vol 34 (1) ◽  
pp. 215-215
Author(s):  
M Nannipieri ◽  
F Cecchetti ◽  
M Anselmino ◽  
S Camastra ◽  
P Nicolini ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Morbid Obesity ◽  
Weight Loss ◽  
Adipose Tissue ◽  
Thyroid Hormone ◽  
Hormone Receptors ◽  
Thyroid Hormone Receptors

TYPE 2 DIABETES MELLITUS REMISSION AND ITS PREDICTION AFTER TWO-STAGE SURGICAL TREATMENT OF PATIENTS WITH MORBID OBESITY

2019 ◽  
Vol 72 (5) ◽  
pp. 739-743
Author(s):  
Oleksandr Yu. Ioffe ◽  
Mykola S. Kryvopustov ◽  
Yuri A. Dibrova ◽  
Yuri P. Tsiura
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Morbid Obesity ◽  
Weight Loss ◽  
Type 2 Diabetes Mellitus ◽  
Surgical Treatment ◽  
Two Stage ◽  
C Peptide ◽  
Peptide Level

Introduction: Morbid obesity (MO) has a significant impact on mortality, health and quality of life of patients. Type 2 diabetes mellitus (T2DM) is a common comorbidity in patients with MO. The aim is to study T2DM remission and to develop a prediction model for T2DM remission after two-stage surgical treatment of patients with MO. Materials and methods: The study included 97 patients with MO. The mean BMI was 68.08 (95% CI: 66.45 - 69.71) kg/m2. 70 (72,2%) patients with MO were diagnosed with T2DM. The first stage of treatment for the main group (n=60) included the IGB placement, for the control group (n=37) - conservative therapy. In the second stage of treatment the patients underwent bariatric surgery. The study addresses such indicators as BMI, percentage of weight loss, percentage of excess weight loss, ASA physical status class, fasting glucose level, HbA1c, C-peptide. Results: Two-stage treatment of morbidly obese patients with T2DM promotes complete T2DM remission in 68.1% of patients. The risk prediction model for failure to achieve complete T2DM remission 12 months after LRYGB based on a baseline C-peptide level has a high predictive value, AUC = 0.84 (95% CI: 0.69-0.93), OR = 0.23 ( 95% CI: 0.08-0.67). Conclusions: Two-stage treatment of patients with MO promotes improvement of carbohydrate metabolism indicators. With a C-peptide level > 3.7 ng/ml, prediction of complete T2DM remission 12 months after Laparoscopic Roux-en-Y Gastric Bypass is favorable.

scholarly journals Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin

2019 ◽  
Vol 104 (9) ◽  
pp. 3647-3660 ◽  
Author(s):  
Akihiro Yoshida ◽  
Yasuhiro Matsubayashi ◽  
Toshiaki Nojima ◽  
Hideki Suganami ◽  
Takahiro Abe ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Weight Loss ◽  
Adipose Tissue ◽  
Glycosylated Hemoglobin ◽  
Term Treatment ◽  
Integrated Analysis ◽  
Long Term Treatment ◽  
Urinary Glucose

Abstract Context Although calorie loss from increased urinary glucose excretion continues after long-term treatment with sodium-glucose cotransporter 2 inhibitors (SGLT2is), the mechanisms of the attenuated weight loss due to SGLT2is are not well known. Objective To examine the mechanism of the attenuated weight loss during long-term treatment with an SGLT2i, tofogliflozin, focusing on the antilipolytic effect of insulin on adipose tissue. Design and Participants An integrated analysis was performed using data from two phase 3 studies of 52 weeks of tofogliflozin administration. The antilipolytic effect was evaluated using adipose tissue insulin resistance (Adipo-IR) calculated from the product of the levels of fasting insulin (f-IRI) and fasting free fatty acids (f-FFAs). Results Data from 774 patients with type 2 diabetes (mean age, 58.5 years; glycosylated hemoglobin, 8.1%; body mass index, 25.6 kg/m2; estimated glomerular filtration rate, 83.9 mL/min/1.73m2; 66% men) were analyzed. Weight loss plateaued between weeks 24 and 52 after decreasing significantly. f-IRI levels decreased significantly from baseline to week 24, and the decrease was maintained until Week 52. f-FFA levels significantly increased, peaked at week 24, then declined from weeks 24 to 52. Adipo-IR levels declined progressively throughout the 52 weeks (−3.6 mmol/L·pmol/L and −6.2 mmol/L·pmol/L at weeks 24 and 52, respectively; P < 0.001 baseline vs weeks 24 and 52 and week 24 vs week 52). Higher baseline Adipo-IR levels were independently associated with greater weight loss at week 52. Conclusion The improved antilipolytic effect in adipose tissue may attenuate progressive lipolysis, leading to attenuating future weight loss induced by an SGLT2i in patients with type 2 diabetes.

scholarly journals «Metabolicheskaya» khirurgiya

2011 ◽  
Vol 8 (3) ◽  
pp. 13-17 ◽  
Author(s):  
Yu I Yashkov ◽  
E V Ershova
Keyword(s):  
Type 2 Diabetes ◽  
Bariatric Surgery ◽  
Morbid Obesity ◽  
Weight Loss ◽  
Conservative Therapy ◽  
Diet Therapy ◽  
Diabetes Control ◽  
Significant Potential ◽  
Maintain Weight Loss

Despite the developed methods of diet therapy in obesity and a variety of pharmacotherapy drugs for type 2 diabetes up to 60% of patients cannot maintain weight loss within 5 years of observation and more than 60% of patients with type 2 diabetes do not achieve adequate diabetes control. With morbid obesity the efficacy of conservative therapy is only 5-10%. Bariatric surgery has demonstrated a significant potential in compensation of obesity-related disorders, including type 2 diabetes.

scholarly journals Exercise Is Required for Visceral Fat Loss in Postmenopausal Women with Type 2 Diabetes

2005 ◽  
Vol 90 (3) ◽  
pp. 1511-1518 ◽  
Author(s):  
I. Giannopoulou ◽  
L. L. Ploutz-Snyder ◽  
R. Carhart ◽  
R. S. Weinstock ◽  
B. Fernhall ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Weight Loss ◽  
Adipose Tissue ◽  
Postmenopausal Women ◽  
Body Fat ◽  
Visceral Fat ◽  
Abdominal Fat ◽  
Percent Body Fat ◽  
Monounsaturated Fat

This study examined the effects of aerobic exercise without weight loss, a hypocaloric high monounsaturated fat diet, and diet plus exercise (D+E) on total abdominal and visceral fat loss in obese postmenopausal women with type 2 diabetes. Thirty-three postmenopausal women (body mass index, 34.6 ± 1.9 kg/m2) were assigned to one of three interventions: a hypocaloric high monounsaturated fat diet alone, exercise alone (EX), and D+E for 14 wk. Aerobic capacity, body composition, abdominal fat distribution (magnetic resonance imaging), glucose tolerance, and insulin sensitivity were measured pre- and postintervention. Body weight (∼4.5 kg) and percent body fat (∼5%) were decreased (P &lt; 0.05) with the D and D+E intervention, whereas only percent body fat (∼2.3%) decreased with EX. Total abdominal fat and sc adipose tissue (SAT) were reduced with the D and D+E interventions (P &lt; 0.05), whereas visceral adipose tissue (VAT) decreased with the D+E and EX intervention, but not with the D intervention. EX resulted in a reduction in total abdominal fat, VAT, and SAT (P &lt; 0.05) despite the lack of weight loss. The reductions in total abdominal fat and SAT explained 32.7% and 9.7%, respectively, of the variability in the changes in fasting glucose levels, whereas the reductions in VAT explained 15.9% of the changes in fasting insulin levels (P &lt; 0.05). In conclusion, modest weight loss, through either D or D+E, resulted in similar improvements in total abdominal fat, SAT, and glycemic status in postmenopausal women with type 2 diabetes; however, the addition of exercise to diet is necessary for VAT loss. These data demonstrate the importance of exercise in the treatment of women with type 2 diabetes.

Sign in / Sign up

Export Citation Format

Share Document